Hypertension Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: April 20, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 30.5 billion |
|
Revenue Forecast in 2031 |
US$ 40.16 billion |
|
Growth Rate |
3.1% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hypertension drugs market was valued at US$ 30.5 billion in 2022 and is expected to register a revenue CAGR of 3.1% to reach US$ 40.16 billion by 2031.
Hypertension Drugs Market Fundamentals
Hypertension drugs are medications used to treat high blood pressure, also known as hypertension. High blood pressure is a common condition in which the force of blood against the walls of arteries is consistently too high, putting a strain on the heart and blood vessels and increasing the risk of heart disease, stroke, and other complications.
Hypertension drugs work by lowering blood pressure through a variety of mechanisms. Some classes of hypertension drugs include diuretics: which increase urine output and reduce the volume of blood in the body; beta-blockers: which block the effects of adrenaline and reduce the workload on the heart; calcium channel blockers: which relax blood vessels and reduce the amount of calcium that enters the heart and blood vessel cells; angiotensin-converting enzyme (ACE) inhibitors: which block the action of a hormone that constricts blood vessels; and angiotensin receptor blockers (ARBs): which block the effects of angiotensin II, a hormone that constricts blood vessels. Hypertension drugs may be used alone or with other drugs to achieve optimal blood pressure control. The choice of medication and dosage depends on the severity of hypertension, other medical conditions the patient may have, and the presence of any side effects.
[86856]
Hypertension Drugs Market Dynamics
The rising prevalence of hypertension is the primary driver for the growth of the global hypertension drugs market. For instance, according to the WHO’s March 2023 factsheet, globally, an estimated 1.28 billion people aged 30-79 years have hypertension, with the majority (two-thirds) residing in low- and middle-income nations. Unhealthy lifestyles, such as lack of exercise, poor diet, and excessive alcohol consumption, contribute to the increasing prevalence of hypertension. Additionally, the rising aging population, which is more prone to high blood pressure issues, is fueling the revenue growth of the global hypertension drugs market. There is an increasing awareness of the health risks associated with hypertension, which has led to a greater demand for hypertension drugs. Moreover, advances in drug delivery systems and novel drug development technologies have led to the development of new and more effective hypertension drugs. Governments in many countries are implementing various initiatives to increase awareness about hypertension and promote early diagnosis and treatment, which drives the demand for the hypertension drugs market.
However, with many hypertension drugs losing patent protection, there is increasing competition from generic drugs, which can decrease prices and revenue for branded hypertension drugs. Many hypertension drugs have side effects that can lead to decreased patient adherence and dissatisfaction with treatment, which can limit their use and sales. Patients may choose to use alternative therapies such as herbal supplements or lifestyle changes to control their blood pressure, which can reduce the demand for hypertension drugs. Strict regulatory requirements and alternative therapies impede the growth of overall market revenue.
Hypertension Drugs Market Ecosystem
The global hypertension drugs market is analyzed from three perspectives: drug class, distribution channel, and region.
Hypertension Drugs Market by Drug Class
[85685]
Based on the drug class, the global hypertension drugs market is segmented into diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, alpha-blockers, renin inhibitors, calcium channel blockers, and others.
The beta blockers segment dominated the market with the principal revenue share in 2022, attributed to their easy availability and being the most popular medication for hypertension. The beta blockers drugs work by blocking the effects of adrenaline on the heart and blood vessels, which reduces the heart rate and blood pressure. Beta-blockers are among the largest and most established hypertension drug market segments. It includes several popular drugs, such as metoprolol, propranolol, atenolol, and bisoprolol. These drugs are available in both generic and branded formulations. Beta-blockers are generally well-tolerated by patients, although they can cause side effects such as fatigue, dizziness, and cold hands and feet. They are often combined with other hypertension drugs, such as diuretics, ACE inhibitors, or calcium channel blockers, to achieve better blood pressure control. These factors contribute to the revenue growth of the beta blockers segment.
The calcium channel blockers segment dominated the market with a significant revenue share in 2022, as these drugs are effective in treating hypertension and have fewer side effects than other drugs. They work by blocking the entry of calcium ions into smooth muscle cells in the heart and blood vessels, which causes the blood vessels to relax and widen, reducing blood pressure. CCBs are also used in treating other conditions, such as angina and arrhythmias, further contributing to their popularity and widespread use. With the increasing prevalence of hypertension and the emergence of new CCBs with better efficacy and safety profiles, the CCBs segment‘s revenue is expected to grow in the hypertension drugs market. These factors contribute to the growth of the calcium channel blockers segment.
Angiotensin-converting enzyme (ACE) inhibitors segment also accounts for a significant market revenue share. They work by inhibiting the action of the angiotensin-converting enzyme, which produces a hormone called angiotensin II. Angiotensin II constricts blood vessels, increases blood pressure, and promotes fluid retention in the body. ACE inhibitors help to relax blood vessels and lower blood pressure, and they are particularly effective in patients with heart failure or diabetes. Common ACE inhibitors include enalapril, lisinopril, and ramipril. They also treat other conditions, such as heart failure and kidney disease.
Hypertension Drugs Market by Distribution Channel
Based on the distribution channel, the global hypertension drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Retail pharmacies are a key player in the hypertension drugs market, with the largest revenue share in 2022. Retail pharmacies offer many hypertension drugs, including prescription medications and over-the-counter (OTC) supplements. Patients can obtain their medications through retail pharmacies by presenting a prescription from their healthcare provider or purchasing OTC supplements for blood pressure management. Retail pharmacies also play a role in patient education and counseling, providing information on proper medication use, potential side effects, and lifestyle changes that can help manage hypertension. These overall factors contribute to the revenue growth of the retail pharmacies segment.
The online pharmacies segment is expected to be the fastest growing segment in terms of revenue share during the forecast period, owing to its convenience of getting the medication at the doorstep. Online pharmacies allow patients to order their medications from the comfort of their own homes and have them delivered directly to their doorstep. Online pharmacies offer many hypertension drugs, including prescription medications and OTC supplements. Patients can search for and compare different medications and prices and have access to customer reviews and ratings to help inform their decisions. Online pharmacies also offer the convenience of automatic refills and reminders, helping patients stay on track with their medication regimens. These overall factors contribute to the revenue growth of the online pharmacies segment.
Hypertension Drugs Market by Region
Based on region, the global hypertension drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global hypertension drugs market with the largest revenue share in 2022, attributed to the region’s high prevalence of hypertension and disorders causing hypertension. Furthermore, rapid and accurate hypertension diagnosis and treatment are needed, identifying persons prone to the condition, providing technically sophisticated healthcare infrastructure, and disease prediction management. Additionally, companies across the region are continuously involved in raising funds to improve their existing process in the hypertension drugs field. It is also expected to improve the hypertension drugs market.
Due to increased knowledge about antihypertensive medications, Asia-Pacific is expected to expand the fastest throughout the projection period. The ever-changing life science industry also promotes market revenue growth in developing nations such as India, China, and Malaysia. Furthermore, companies across the region are continuously involved in launching new and novel medications, which is also helping in regional revenue growth. For instance, in May 2022, Zydus Lifesciences Limited, a subsidiary of Zydus Worldwide DMCC, received tentative approval from the US Food and Drug Administration (USFDA) to market Selexipag Tablets in the following strengths: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,000 mcg, 1,200 mcg, 1,400 mcg, and 1,600 mcg (USRLD: Uptravi). Selexipag treats pulmonary arterial hypertension (PAH) in adults to postpone disease development and lower the risk of hospitalization for PAH. Selexipag is an agonist of the prostacyclin receptor. The medicine will be produced at the group’s formulation plant in Ahmedabad’s SEZ.
Hypertension Drugs Market Competitive Landscape
The prominent players operating in the global hypertension drugs market are:
Hypertension Drugs Market Strategic Developments
The global hypertension drugs market was valued at US$ 30.5 billion in 2022.
The expected size of the global hypertension drugs market in 2031 is US$ 40.16 billion.
The expected revenue CAGR of the hypertension drugs market during the forecast period is 3.1% from 2023 to 2031.
The strict regulatory requirements and alternative therapies restrict the global hypertension drugs market revenue growth to its full potential.
Some prominent players operating in the global hypertension drugs market are Zydus Lifesciences Limited, Hanmi Pharmaceutical, Alembic Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim GmbH.
*Insights on financial performance are subject to the availability of information in the public domain